Sign In
to Vote &
Create Storyboards.
 
Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye. The candidate molecule, ML7, is the first in a new therapeutic class. It has the potential to bring an effective, targeted therapeutic response to the millions of people who suffer from dry eye syndromes.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard